Across TCGA pan-cancer cohorts, CC2D2A Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CC2D2A data layer compared with 28 for mass-spec protein and 4 for mass-spec protein.
The strongest signal is observed in stomach adenocarcinoma (STAD), where higher CC2D2A Mutation is associated with better overall survival. In most high-consensus cancer types, elevated CC2D2A expression acts as an unfavorable survival marker, although some lineages such as STAD show a favorable association.
STAD, UCEC, and LUAD are the cancer types where CC2D2A Mutation most reproducibly stratifies survival.